HbA1c converter to glucose tools help translate your glycated haemoglobin result into an estimated average blood glucose level — a figure many people find easier to understand alongside their day-to-day readings. HbA1c is the cornerstone blood test for diagnosing and monitoring diabetes in the UK, reported in mmol/mol under IFCC standardisation. Yet the laboratory figure alone can feel abstract. Converting it to an estimated average glucose (eAG) in mmol/L bridges that gap, giving patients and clinicians a more intuitive sense of longer-term blood sugar control. This article explains the science, the validated conversion formulae, NHS and NICE reference ranges, and the clinical factors that can affect accuracy.

What Is HbA1c and How Does It Relate to Blood Glucose?

HbA1c measures the proportion of glycated haemoglobin to reflect average blood glucose over 2–3 months, making it more stable than a single finger-prick reading. In the UK it is reported in mmol/mol (IFCC units).

HbA1c — formally known as glycated haemoglobin — is a blood test that reflects your average blood glucose (blood sugar) levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin, the protein found inside red blood cells. Because red blood cells have a lifespan of approximately 90 to 120 days, the proportion of haemoglobin that has become glycated provides a reliable snapshot of longer-term glucose control, rather than a single moment in time.

Importantly, HbA1c is a weighted average: glucose levels from the most recent four to eight weeks contribute more to the result than those from earlier in the three-month period. This means a recent improvement — or deterioration — in glucose control will have a proportionally greater influence on the result than changes that occurred two to three months ago.

This is what makes HbA1c fundamentally different from a finger-prick blood glucose test. A standard glucose reading — whether fasting or random — captures blood sugar at one specific point, which can fluctuate considerably depending on meals, physical activity, stress, or illness. HbA1c, by contrast, smooths out these daily variations, making it a more stable and reproducible marker for diagnosing and monitoring type 2 diabetes, and for assessing glycaemic control in people already living with diabetes.

In the UK, HbA1c is reported in millimoles per mole (mmol/mol), following the International Federation of Clinical Chemistry (IFCC) standardisation adopted in 2009. Older reports may still reference the DCCT/NGSP percentage (%) format used prior to this change. Understanding the relationship between HbA1c and actual blood glucose levels is clinically important — it helps both patients and clinicians translate a laboratory figure into a meaningful, real-world measure of how blood sugar has been behaving over time. This is where an HbA1c converter to glucose becomes a practical and educational tool.

When HbA1c should not be used for diagnosis

NICE guidance (NG28) and NHS clinical practice specify several situations in which HbA1c is not a reliable diagnostic tool and should not be used to diagnose diabetes:

• Pregnancy and within two months postpartum — HbA1c is not used to diagnose gestational diabetes (see NICE NG3)

• Children and young people — alternative diagnostic criteria apply

• Suspected type 1 diabetes — clinical presentation and other investigations take precedence

• Conditions affecting red blood cell turnover or haemoglobin structure — including haemolytic anaemia, haemoglobin variants (e.g., sickle cell trait), iron deficiency anaemia, recent blood transfusion, or erythropoietin therapy

• Chronic kidney disease (CKD) — altered red cell lifespan can make HbA1c unreliable

In these circumstances, plasma glucose measurements (fasting or oral glucose tolerance test) are used instead. If you are unsure whether HbA1c is the appropriate test for your situation, speak with your GP or diabetes care team.

How to Convert HbA1c to an Estimated Average Glucose Level

The validated IFCC formula is: eAG (mmol/L) = (0.1459 × HbA1c in mmol/mol) + 0.8366. For example, an HbA1c of 48 mmol/mol corresponds to an eAG of approximately 7.8 mmol/L.

The concept of estimated average glucose (eAG) was developed to help translate HbA1c values into units that patients are more familiar with from home glucose monitoring — typically millimoles per litre (mmol/L) in the UK. The conversion is based on mathematical equations derived from large clinical studies, most notably the A1c-Derived Average Glucose (ADAG) study (Nathan et al., NEJM 2008), which correlated HbA1c measurements with continuous glucose monitoring data across diverse populations.

The two validated conversion formulae are:

Using NGSP/DCCT percentage units: eAG (mmol/L) = (1.5944 × HbA1c in %) − 2.5944

Using IFCC units (mmol/mol), as reported in the UK: eAG (mmol/L) = (0.1459 × HbA1c in mmol/mol) + 0.8366

To illustrate this in practice:

• An HbA1c of 48 mmol/mol (6.5%) — the diagnostic threshold for type 2 diabetes in the UK — corresponds to an eAG of approximately 7.8 mmol/L

• An HbA1c of 53 mmol/mol (7.0%) equates to an eAG of approximately 8.6 mmol/L

• An HbA1c of 75 mmol/mol (9.0%) corresponds to an eAG of approximately 11.8 mmol/L

It is important to note that eAG is an estimate, not a direct measurement. It represents a mathematical average and does not capture glucose variability — meaning it cannot reveal episodes of hypoglycaemia or post-meal spikes. Additionally, eAG is not routinely reported by all UK laboratories and is not mandated by NICE; it is best regarded as an educational aid to help contextualise HbA1c results.

The eAG estimate may also be unreliable in certain circumstances, including pregnancy, haemoglobin variants, anaemia, CKD, and following recent blood transfusion — the same conditions that can affect HbA1c accuracy more broadly (see the section below on factors affecting results). Patients should therefore use eAG as a complementary guide alongside, rather than a replacement for, regular blood glucose monitoring where this is clinically indicated. Many online HbA1c converter to glucose tools use these validated formulae and can be a helpful educational resource when used appropriately.

Understanding Your Results: NHS and NICE Reference Ranges

NICE NG28 defines normal as below 42 mmol/mol, non-diabetic hyperglycaemia as 42–47 mmol/mol, and type 2 diabetes as 48 mmol/mol or above on confirmed testing. Individualised targets apply for people already on diabetes treatment.

In the UK, NICE guidelines (NG28) and NHS clinical practice use clearly defined HbA1c thresholds to guide diagnosis and management decisions. Understanding where your result sits within these ranges — and what the corresponding estimated average glucose means — can help you engage more meaningfully with your healthcare team.

Diagnostic and monitoring thresholds (NICE NG28):

• Below 42 mmol/mol (below 6.0%): Normal range — eAG approximately below 6.9 mmol/L

• 42–47 mmol/mol (6.0–6.4%): Non-diabetic hyperglycaemia (sometimes called prediabetes) — eAG approximately 7.0–7.7 mmol/L. NICE recommends lifestyle intervention and annual HbA1c monitoring in this group; referral to the NHS Diabetes Prevention Programme (NHS DPP) should be considered.

• 48 mmol/mol (6.5%) or above: Indicative of type 2 diabetes (when confirmed on a second test in asymptomatic individuals) — eAG approximately 7.8 mmol/L or above

Important diagnostic caveats: HbA1c should not be used to diagnose diabetes in pregnancy, in children and young people, in suspected type 1 diabetes, or in individuals with conditions that affect red blood cell turnover or haemoglobin structure (see the first section for full details). In these situations, plasma glucose testing is required.

For people already diagnosed with diabetes, NICE NG28 recommends individualised HbA1c targets. For most adults with type 2 diabetes managed with lifestyle measures or non-hypoglycaemic medications, a target of 48 mmol/mol (6.5%) is advised. For those on insulin or sulfonylureas — where the risk of hypoglycaemia is higher — a target of 53 mmol/mol (7.0%) is generally more appropriate. If you experience side effects from your diabetes medicines, including symptoms of hypoglycaemia, you or your healthcare professional can report these via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

The NHS also recognises that targets should be personalised, taking into account age, comorbidities, frailty, and patient preference. Importantly, very low HbA1c values in older or frail individuals may actually signal increased risk of hypoglycaemia, which carries its own serious consequences. If your HbA1c result falls outside your expected range — whether higher or lower than anticipated — it is advisable to discuss this with your GP or diabetes care team rather than adjusting treatment independently.

Factors That Can Affect HbA1c and Glucose Readings

Haemolytic anaemia, haemoglobin variants, pregnancy, recent blood transfusion, and advanced CKD can falsely lower HbA1c, whilst iron deficiency anaemia and splenectomy can falsely raise it. Alternative monitoring such as fructosamine or CGM may be needed in these situations.

Whilst HbA1c is a robust and widely validated test, several physiological and clinical factors can influence its accuracy, potentially causing results to appear falsely high or falsely low — independent of actual blood glucose control. Being aware of these factors is important for interpreting results correctly.

Conditions that may falsely lower HbA1c:

• Haemolytic anaemia — increased red blood cell turnover means fewer cells have been exposed to glucose for the full 90-day period, reducing measured glycation

• Recent blood transfusion or acute blood loss — introduces donor red cells with no prior glycation history, diluting the HbA1c result

• Erythropoietin therapy — stimulates production of new red cells, shortening average cell age and reducing HbA1c

• Haemoglobin variants (e.g., sickle cell trait, HbS, HbC) — may interfere with certain laboratory assay methods, producing spuriously low or unreliable results

• Pregnancy — particularly in the second and third trimesters, due to increased red cell turnover; HbA1c is not recommended as a diagnostic tool in pregnancy (NICE NG3)

• Severe liver disease and alcoholism — can alter red cell turnover and affect assay reliability

Conditions that may falsely raise HbA1c:

• Iron deficiency anaemia (untreated) — reduced red cell turnover prolongs haemoglobin exposure to glucose, increasing measured glycation. Note that treating iron deficiency anaemia can cause HbA1c to fall independently of any change in true glycaemic control, as normal erythropoiesis is restored.

• Vitamin B12 or folate deficiency — reduced red cell production may prolong cell lifespan

• Splenectomy — prolonged red cell survival increases glycation time

Chronic kidney disease (CKD): The effect of CKD on HbA1c is variable and depends on disease severity and the assay method used. In advanced CKD, shortened red cell lifespan (due to uraemia and associated anaemia) typically causes HbA1c to be spuriously low, potentially underestimating true glycaemic exposure. In some cases, assay interference may produce unpredictable results. For people with advanced CKD, alternative monitoring approaches — such as fructosamine testing or continuous glucose monitoring (CGM) — may be more appropriate. This is consistent with NICE NG28 cautions on HbA1c reliability and NICE NG203 guidance on CKD management.

Beyond HbA1c itself, day-to-day blood glucose readings can also be affected by factors such as acute illness, corticosteroid use, significant changes in diet or physical activity, and psychological stress — all of which can cause temporary elevations. Certain medications, including thiazide diuretics, antipsychotics, and glucocorticoids, are known to raise blood glucose levels and may therefore influence both HbA1c and eAG values over time. The dose and duration of treatment, as well as individual patient factors, will affect the degree of impact.

If you suspect your HbA1c result may not accurately reflect your glucose control — for example, if your home readings consistently suggest better or worse control than your HbA1c implies — raise this with your GP or diabetes specialist. In some cases, alternative monitoring methods such as fructosamine testing or CGM may be more appropriate. Suspected adverse effects of any medicine, including unexpected changes in blood glucose, can be reported via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions